Find Anakinra manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

Synopsis

ACTIVE PHARMA INGREDIENTS

0

API Suppliers

API Suppliers

0

USDMF

US DMFs Filed

0

CEP/COS

CEP/COS Certifications

0

JDMF

JDMFs Filed

0

EU WC

EU WC

0

KDMF

KDMF

0

NDC API

NDC API

0

VMF

NDC API

0

Listed Suppliers

Other Suppliers

API REF. PRICE (USD/KG)

$
$ 0

MARKET PLACE

0INTERMEDIATES

FINISHED DOSAGE FORMULATIONS

0

South Africa

South Africa

0

Listed Dossiers

Listed Dossiers

FDF Dossiers

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

0

EDQM

0

USP

0

JP

0

Others

PATENTS & EXCLUSIVITIES

0

US Patents

0

US Exclusivities

DIGITAL CONTENT

0

Data Compilation #PharmaFlow

0

Stock Recap #PipelineProspector

0

Weekly News Recap #Phispers

16 RELATED EXCIPIENT COMPANIES

33EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: Interleukin1 receptor antagonist (human isoform x reduced),n2-l-methionyl- (9ci)
Molecular Formula
C20H23N5O7S2
Molecular Weight
509.6  g/mol
InChI Key
HMLGSIZOMSVISS-ONJSNURVSA-N

Anakinra
1 2D Structure

Anakinra

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
(7R)-7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(2,2-dimethylpropanoyloxymethoxyimino)acetyl]amino]-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
2.1.2 InChI
InChI=1S/C20H23N5O7S2/c1-5-9-6-33-16-12(15(27)25(16)13(9)17(28)29)23-14(26)11(10-7-34-19(21)22-10)24-32-8-31-18(30)20(2,3)4/h5,7,12,16H,1,6,8H2,2-4H3,(H2,21,22)(H,23,26)(H,28,29)/b24-11-/t12-,16?/m1/s1
2.1.3 InChI Key
HMLGSIZOMSVISS-ONJSNURVSA-N
2.1.4 Canonical SMILES
CC(C)(C)C(=O)OCON=C(C1=CSC(=N1)N)C(=O)NC2C3N(C2=O)C(=C(CS3)C=C)C(=O)O
2.1.5 Isomeric SMILES
CC(C)(C)C(=O)OCO/N=C(/C1=CSC(=N1)N)\C(=O)N[C@H]2C3N(C2=O)C(=C(CS3)C=C)C(=O)O
2.2 Synonyms
2.2.1 Depositor-Supplied Synonyms

1. Interleukin1 Receptor Antagonist (human Isoform X Reduced),n2-l-methionyl- (9ci)

2.3 Create Date
2015-02-16
3 Chemical and Physical Properties
Molecular Weight 509.6 g/mol
Molecular Formula C20H23N5O7S2
XLogP31.1
Hydrogen Bond Donor Count3
Hydrogen Bond Acceptor Count12
Rotatable Bond Count10
Exact Mass509.10389044 g/mol
Monoisotopic Mass509.10389044 g/mol
Topological Polar Surface Area227 Ų
Heavy Atom Count34
Formal Charge0
Complexity961
Isotope Atom Count0
Defined Atom Stereocenter Count1
Undefined Atom Stereocenter Count1
Defined Bond Stereocenter Count1
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count1

Drugs in Development

read-more
read-more

Details:

Kineret (anakinra) is an anti-inflammatory medicine that neutralises the biological activity of both cytokines IL-1α and β, which play a role in COVID19-induced hyperinflammation.


Lead Product(s): Anakinra

Therapeutic Area: Pulmonary/Respiratory Diseases Brand Name: Kineret

Study Phase: ApprovedProduct Type: Large molecule

Sponsor: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable November 10, 2022

blank

01

Biotech Digital Meet
Not Confirmed
Biotech Digital Meet
Not Confirmed

Details : Kineret (anakinra) is an anti-inflammatory medicine that neutralises the biological activity of both cytokines IL-1α and β, which play a role in COVID19-induced hyperinflammation.

Product Name : Kineret

Product Type : Large molecule

Upfront Cash : Not Applicable

November 10, 2022

blank

Details:

The study demonstrated that patients treated with anakinra were significantly more improved than those treated with placebo. Early and targeted use of anakinra, in addition to current SOC, reduces risk of death, reduces ICU admission and increases chances of full recovery.


Lead Product(s): Anakinra

Therapeutic Area: Infections and Infectious Diseases Brand Name: Kineret

Study Phase: Phase IIIProduct Type: Large molecule

Sponsor: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable September 03, 2021

blank

02

Biotech Digital Meet
Not Confirmed
Biotech Digital Meet
Not Confirmed

Details : The study demonstrated that patients treated with anakinra were significantly more improved than those treated with placebo. Early and targeted use of anakinra, in addition to current SOC, reduces risk of death, reduces ICU admission and increases chance...

Product Name : Kineret

Product Type : Large molecule

Upfront Cash : Not Applicable

September 03, 2021

blank

Details:

In patients with a poor prognosis, early and targeted use of anakinra in addition to existing standard of care reduced death or progression to severe respiratory failure, while increasing the number of patients discharged with no evidence of COVID-19 infection.


Lead Product(s): Anakinra

Therapeutic Area: Infections and Infectious Diseases Brand Name: Kineret

Study Phase: Phase IIIProduct Type: Large molecule

Sponsor: Hellenic Institute for the Study of Sepsis

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 03, 2021

blank

03

Biotech Digital Meet
Not Confirmed
Biotech Digital Meet
Not Confirmed

Lead Product(s) : Anakinra

Therapeutic Area : Infections and Infectious Diseases

Highest Development Status : Phase III

Partner/Sponsor/Collaborator : Hellenic Institute for the Study of Sepsis

Deal Size : Not Applicable

Deal Type : Not Applicable

Details : In patients with a poor prognosis, early and targeted use of anakinra in addition to existing standard of care reduced death or progression to severe respiratory failure, while increasing the number of patients discharged with no evidence of COVID-19 inf...

Product Name : Kineret

Product Type : Large molecule

Upfront Cash : Not Applicable

May 03, 2021

blank

Details:

NICE has approved Kineret (anakinra) to treat systemic juvenile idiopathic arthritis (sJIA) in people aged eight months or over with a body weight of 10kg or more, who have not responded to at least one conventional disease modifying antirheumatic drug (DMARD).


Lead Product(s): Anakinra

Therapeutic Area: Rare Diseases and Disorders Brand Name: Kineret

Study Phase: ApprovedProduct Type: Large molecule

Sponsor: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 31, 2021

blank

04

Biotech Digital Meet
Not Confirmed
Biotech Digital Meet
Not Confirmed

Details : NICE has approved Kineret (anakinra) to treat systemic juvenile idiopathic arthritis (sJIA) in people aged eight months or over with a body weight of 10kg or more, who have not responded to at least one conventional disease modifying antirheumatic drug (...

Product Name : Kineret

Product Type : Large molecule

Upfront Cash : Not Applicable

March 31, 2021

blank

Details:

Kineret® is an interleukin-1 receptor antagonist that in the US is indicated for rheumatoid arthritis, in patients 18 years of age or older who have failed 1 or more DMARDs.


Lead Product(s): Anakinra

Therapeutic Area: Genetic Disease Brand Name: Kineret

Study Phase: ApprovedProduct Type: Large molecule

Sponsor: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable February 16, 2021

blank

05

Biotech Digital Meet
Not Confirmed
Biotech Digital Meet
Not Confirmed

Details : Kineret® is an interleukin-1 receptor antagonist that in the US is indicated for rheumatoid arthritis, in patients 18 years of age or older who have failed 1 or more DMARDs.

Product Name : Kineret

Product Type : Large molecule

Upfront Cash : Not Applicable

February 16, 2021

blank
  • Development Update

Details:

The trial, which began in May, involves 20 children with Sanfilippo syndrome, who will be given anakinra, which blocks the activity of interleukin-1 (IL-1), a protein in the body that causes joint damage, thereby reducing inflammation.


Lead Product(s): Anakinra

Therapeutic Area: Genetic Disease Brand Name: Kineret

Study Phase: Phase II/ Phase IIIProduct Type: Peptide

Sponsor: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 24, 2020

blank

06

The Lundquist Institute

Country
arrow
Biotech Digital Meet
Not Confirmed

The Lundquist Institute

Country
arrow
Biotech Digital Meet
Not Confirmed

Details : The trial, which began in May, involves 20 children with Sanfilippo syndrome, who will be given anakinra, which blocks the activity of interleukin-1 (IL-1), a protein in the body that causes joint damage, thereby reducing inflammation.

Product Name : Kineret

Product Type : Peptide

Upfront Cash : Not Applicable

June 24, 2020

blank

Details:

First study to report use of anakinra to treat COVID-19 infection found that high-dose anakinra was safe and was associated with a 90% survival rate and reduced respiratory symptoms associated with severe COVID-19 infection.


Lead Product(s): Anakinra

Therapeutic Area: Infections and Infectious Diseases Brand Name: Undisclosed

Study Phase: Phase II/ Phase IIIProduct Type: Large molecule

Sponsor: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 08, 2020

blank

07

Biotech Digital Meet
Not Confirmed
Biotech Digital Meet
Not Confirmed

Details : First study to report use of anakinra to treat COVID-19 infection found that high-dose anakinra was safe and was associated with a 90% survival rate and reduced respiratory symptoms associated with severe COVID-19 infection.

Product Name : Undisclosed

Product Type : Large molecule

Upfront Cash : Not Applicable

May 08, 2020

blank

Details:

Swedish Orphan Biovitrum AB will begin a short-term clinical study to evaluate the efficacy and safety of anakinra and emapalumab in the treatment of hyper-inflammatory syndrome in COVID-19 disease.


Lead Product(s): Anakinra

Therapeutic Area: Infections and Infectious Diseases Brand Name: Undisclosed

Study Phase: Phase II/ Phase IIIProduct Type: Large molecule

Sponsor: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 18, 2020

blank

08

Biotech Digital Meet
Not Confirmed
Biotech Digital Meet
Not Confirmed

Details : Swedish Orphan Biovitrum AB will begin a short-term clinical study to evaluate the efficacy and safety of anakinra and emapalumab in the treatment of hyper-inflammatory syndrome in COVID-19 disease.

Product Name : Undisclosed

Product Type : Large molecule

Upfront Cash : Not Applicable

March 18, 2020

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Related Excipient Companies

Upload your portfolio for free, ask us

Excipients by Applications

Click here to find the perfect excipient manufacturers by their capabilities

Solubilizers

read-more
read-more

Parenteral

read-more
read-more

Topical

read-more
read-more

Emulsifying Agents

read-more
read-more

Thickeners and Stabilizers

read-more
read-more

Film Formers & Plasticizers

read-more
read-more

Surfactant & Foaming Agents

read-more
read-more

Co-Processed Excipients

read-more
read-more

Direct Compression

read-more
read-more

Rheology Modifiers

read-more
read-more

API Stability Enhancers

read-more
read-more

Digital Content read-more

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

Global Sales Information

Do you need Business Intel? Ask us

Market Place

Do you need sourcing support? Ask us

Patents & EXCLUSIVITIES

Check the patents & exclusivity for this product

ABOUT THIS PAGE

Looking for / Anakinra API manufacturers, exporters & distributors?

Anakinra manufacturers, exporters & distributors 1

35

PharmaCompass offers a list of Anakinra API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Anakinra manufacturer or Anakinra supplier for your needs.

Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Anakinra manufacturer or Anakinra supplier.

PharmaCompass also assists you with knowing the Anakinra API Price utilized in the formulation of products. Anakinra API Price is not always fixed or binding as the Anakinra Price is obtained through a variety of data sources. The Anakinra Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.

API | Excipient name

Anakinra

Synonyms

Interleukin1 receptor antagonist (human isoform x reduced),n2-l-methionyl- (9ci)

Anakinra Manufacturers

A Anakinra manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Anakinra, including repackagers and relabelers. The FDA regulates Anakinra manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Anakinra API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.

Anakinra Suppliers

A Anakinra supplier is an individual or a company that provides Anakinra active pharmaceutical ingredient (API) or Anakinra finished formulations upon request. The Anakinra suppliers may include Anakinra API manufacturers, exporters, distributors and traders.

Anakinra GMP

Anakinra Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.

GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).

PharmaCompass offers a list of Anakinra GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Anakinra GMP manufacturer or Anakinra GMP API supplier for your needs.

Anakinra CoA

A Anakinra CoA (Certificate of Analysis) is a formal document that attests to Anakinra's compliance with Anakinra specifications and serves as a tool for batch-level quality control.

Anakinra CoA mostly includes findings from lab analyses of a specific batch. For each Anakinra CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.

Anakinra may be tested according to a variety of international standards, such as European Pharmacopoeia (Anakinra EP), Anakinra JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Anakinra USP).

Inform the supplier about your product requirements, specifying if you need a product with particular monograph like EP (Ph. Eur.), USP, JP, BP, or any other quality. In addition, clarify whether you need hydrochloride (HCl), anhydricum, base, micronisatum or a specific level of purity. To find reputable suppliers, utilize the filters and select those certified by GMP, FDA, or any other certification as per your requirement.
For your convenience, we have listed synonyms and CAS numbers to help you find the best supplier. The use of synonyms and CAS numbers can be helpful in identifying potential suppliers, but it is crucial to note that they might not always indicate the exact same product. It is important to confirm the product details with the supplier before making a purchase to ensure that it meets your requirements.
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty